Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Brief summary

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

acronym

REMAP-CAP

status

RECRUITING

phase

PHASE3

study type

INTERVENTIONAL

enrollment

20000

sponsor

UMC Utrecht

conditions

Community-acquired Pneumonia, Influenza, COVID-19

interventions

DRUG: Ceftriaxone; DRUG: Moxifloxacin or Levofloxacin; DRUG: Piperacillin-tazobactam; DRUG: Ceftaroline; DRUG: Amoxicillin-clavulanate; DRUG: Standard course macrolide; DRUG: Extended course macrolide; OTHER: No systemic corticosteroid; DRUG: Fixed-duration Hydrocortisone; DRUG: Shock-dependent hydrocortisone

start date

2016-04-11

start date type

ACTUAL

primary completion date

2026-02-01

has results

false

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters